General
Preferred name
LENALIDOMIDE
Synonyms
3-(4-Amino-1-oxo-1,3-dihydro-2h-isoindol-2-yl)piperidine-2,6-dione ()
CC-5013 hydrochloride ()
Lenalidomide (hydrochloride) ()
Revlimid ()
CC5013 ()
CC-5013 ()
Lenalidomide (CC-5013) ()
ENMD-0997 ()
Lenalidomide (hemihydrate) ()
CC-5013 hemihydrate ()
Lenalidomide hemihydrate ()
Lenalidomide hydrochloride ()
1b(lena) ()
Lenalidomide ()
LenalidomideRevlimidCC-50133-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)- ()
LENALIDOMIDE HYDROCHLORIDE MONOHYDRATE ()
Lenalidomide-d5 ()
CDC-501 ()
SYP-1512 ()
Lenalidomide mylan ()
Lenalidomida ()
NSC-747972 ()
Lenalidomide accord ()
Lenalidomide krka d.d. ()
Lenalidomide krka d.d. novo mesto (previously lenalidomide krka) ()
Lenalidomide krka (previously lenalidomide krka d.d. novo mesto) ()
P&D ID
PD004118
CAS
191732-72-6
443912-14-9
1243329-97-6
847871-99-2
1227162-34-6
Tags
available
molecular glue
PROTAC
drug
Approved by
FDA
PMDA
EMA
First approval
2021
2005
Drug indication
Mantle cell lymphoma
Multiple myeloma
Myelodysplastic syndrome
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
HALF-LIFE Healthy subjects = 3 hours;; Multiple myeloma or MDS patients = 3 - 5 hours.
DESCRIPTION Lenalidomide is a derivative of with anti-inflammatory and anti-cancer actions. (GtoPdb)
DESCRIPTION Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].
DESCRIPTION Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].
DESCRIPTION Potent pan Pim kinase inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Lenalidomide is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of thalidomide. It is used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome. (Enamine Bioactive Compounds)
DESCRIPTION Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products. (TargetMol Bioactive Compound Library)
DESCRIPTION Lenalidomide is a TNF-α secretion inhibitor. (BOC Sciences Bioactive Compounds)
DESCRIPTION Lenalidomide hemihydrate is a derivative of Thalidomide, an orally active immunomodulator that acts as a molecular gel. It is a ligand for the ubiquitin E3 ligase cereblon, which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase. (TargetMol Bioactive Compound Library)
DESCRIPTION Lenalidomideis a derivative of thalidomide introduced in 2004. Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM. (BOC Sciences Bioactive Compounds)
Cell lines
133
Organisms
1
Compound Sets
30
AdooQ Bioactive Compound Library
A10522
Axon Medchem Screening Library
1793
BOC Sciences Bioactive Compounds
lenalidomide-hemihydrate-cas-847871-99-2-item-84-463648
lenalidomide-hydrochloride-cas-1243329-97-6-item-84-463148
Cayman Chemical Bioactives
14643
22370
ChEMBL Approved Drugs
CHEMBL848
CHEMBL6068337
ChEMBL Drugs
CHEMBL848
CHEMBL6068337
CZ-OPENSCREEN Bioactive Library
DrugBank
DB00480
DrugBank Approved Drugs
DB00480
DrugCentral
3317
DrugCentral Approved Drugs
3317
DrugMAP
DM6Q7U4
DrugMAP Approved Drugs
DM6Q7U4
Enamine Bioactive Compounds
EBC-11297
Enamine BioReference Compounds
Guide to Pharmacology
7331
LINCS compound set
10418-101
MedChem Express Bioactive Compound Library
HY-A0003
HY-A0003B
MolGlueDB
828
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
F0P408N6V4
NIH Approved Oncology Drugs
91148448
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
lenalidomide-s1029
TargetMol Bioactive Compound Library
T1642
T22922
The Spectrum Collection
Tocris Bioactive Compound Library
6305
Welcome Trust Cancer Drugs
1020
External IDs
70
Properties
(calculated by RDKit )
Molecular Weight
259.1
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
1
cLogP
0.03
TPSA
92.5
Fraction CSP3
0.31
Chiral centers
1.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
TNF alpha
Ligand for E3 Ligase
Cereblon
Molecular Glues
TNF-α
Apoptosis
TNF Receptor
TNFa inhibitor
Ligands for E3 Ligase
Apoptosis related,Caspase,E3 Ligase ,E3 ligase Ligand,TNF-alpha,VEGFR
Primary Target
Ubiquitin E3 Ligases
MOA
TNF
DDB1-CRBN modulator
Angiogenesis Inhibitors
TNF-alpha Production Inhibitors
Member status
member
Therapeutic Indication
Myelodysplasia
Therapeutic Class
Anticancer
Anticancer Agents
Source data